

# Economics of TB: Securing financing under UHC



**Carlo Irwin A. Panelo**

Department of Clinical Epidemiology

UP College of Medicine

June 20, 2022




# Economic burden of TB is substantial

- Economic costs of TB is substantial (Peabody et al, 2009)
  - 500,000 DALYS;9% of YLL
  - P8B in economic losses
  - Up to P1.6B in annual treatment cost
- Nearly half of families with TB incur catastrophic spending (Florentino et al., 2022)
  - USD 601 overall mean total cost including pre- and post-diagnostic costs; 5X in DRTB
  - Around 80% of the total cost of TB are from direct non-medical costs and income loss, respectively



# TB care is funded mostly out-of-pocket



Source: Panelo et al., 2020



# How much does it cost to treat TB?

- Adult DSTB = P 6,725
- Adult MDR = P 374,630
- Adult LTBI = P 4,092

Source: USAID's ProtectHealth 2022



# Recommendations for TB elimination

- Develop an operational plan from within PhilSTEP1 to match elimination targets
  - Set phased elimination targets
  - Identify focus areas to maximize yield
  - Identify priority populations with heavy burden
  - Assign accountability to specific regions and LGUs
  - Secure and provide financing mainly through DOH grants
- Test models/approaches prior to scale up, e.g. CiTEC
  - Focus on urban poor
  - Generate demand through community health workers/navigators
  - Employ active case finding measures
  - Contract private providers as part of provider network
  - Monitor closely to sustain and complete treatment



# Active case finding yields more than combination strategies

Elasticity (labor)	Viet Nam		Lao People's Democratic Republic	
	$\alpha = 0.1$	$\alpha = 0.5$	$\alpha = 0.1$	$\alpha = 0.5$
<b>TB care (baseline) compared with no TB care (counterfactual)</b>				
<b>Total cost</b>	\$ 378,000,000		\$ 23,000,000	
<b>Financed by savings*</b>	\$ 185,000,000		\$ 5300,000	
<b>Gain in labor</b>	3795,200		188,500	
<b>Gain in GDP</b>	\$ 18.4 billion	\$ 10.7 billion	\$ 92 million	\$ 549 million
<b>Return on investment</b>	\$ 49	\$ 28	\$ 4	\$ 24
<b>ACF (moderate, targeted) compared with baseline</b>				
<b>Total cost</b>	\$ 218,611,000		\$ 9197,000	
<b>Gain in labor</b>	126,300		10,100	
<b>Gain in GDP</b>	\$ 586 million	\$ 297 million	\$ 3.9 million	\$ 26.2 million
<b>Return on investment</b>	\$ 2.70	\$ 1.40	\$ 0.40	\$ 2.90
<b>Combination strategy compared with baseline</b>				
<b>Total cost</b>	\$ 989,568,000		\$ 49,096,000	
<b>Gain in labor</b>	417,500		56,000	
<b>Gain in GDP</b>	\$ 1.82 billion	\$ 890 million	\$ 356,000	\$ -4.5 million**
<b>Return on investment</b>	\$ 1.80	\$ 0.90	\$ 0.00	\$ -0.10**

Source: Estil et al., 2021



# Securing financing for TB under UHC

TB control measures	Population-based and/or merit good	Individual-based	Non-medical costs
Information and demand generation	X		
Screening and confirmation	X*		
Treatment and monitoring		X*	
Social support			X
Enabling environment			X

\*overlaps in DOH, LGU and PhilHealth support





# Thank you!

[capanelo@up.edu.ph](mailto:capanelo@up.edu.ph)

